news
Canagliflozin may not be associated with fracture risk in diabetes patients
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes...
List view / Grid view
Type 2 Diabetes
news
Insulin supply chain transparency needed to prevent price hikes
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
news
Lixisenatide prevents damage to kidneys in diabetes and CVD patients
Lixisenatide has shown prevention of kidney damage in patients with type 2 diabetes or cardiovascular disease through a study by the EASD...
news
Statins study questions their widespread use in the healthy elderly
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
news
Collaboration to launch for the treatment of type 2 diabetes in China
Two companies will work closely together on future development, distribution, promotion, access, marketing and sales of Invokana (canagliflozin) for type 2 diabetes...
news
GDM points toward heightened risk of heart disease
Women who have gestational diabetes mellitus during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future...
news
Interactive app provides disease management tool for diabetes
Scientists have developed an online interactive app to help motivate patients to be more active in managing their disease...
news
Ozempic approved for the treatment of type 2 diabetes
Health Canada has approved Ozempic to improve glycemic control in adults with type 2 diabetes mellitus when metformin is not tolerated or contraindicated...
news
FDA approves Admelog, the first follow-on insulin product to treat diabetes
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
news
A risk factor for drug-induced skin disease identified
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
news
FDA approves Bydureon BCise for patients with type-2 diabetes
The FDA has approved Bydureon BCise for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines...
news
Oral semaglutide shows promise for type 2 diabetes
Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes...
article
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
news
LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
news
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
